Deciphera Pharmaceuticals Stock Forecast, Price & News

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

Is Deciphera Pharmaceuticals a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

How has Deciphera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DCPH shares have decreased by 81.8% and is now trading at $8.07.
View which stocks have been most impacted by COVID-19.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Deciphera Pharmaceuticals.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its earnings results on Tuesday, November, 2nd. The company reported ($1.37) EPS for the quarter, missing the Zacks' consensus estimate of ($1.29) by $0.08. Deciphera Pharmaceuticals had a negative net margin of 300.00% and a negative trailing twelve-month return on equity of 58.56%. During the same period in the previous year, the company earned ($1.13) EPS.
View Deciphera Pharmaceuticals' earnings history.

What price target have analysts set for DCPH?

12 Wall Street analysts have issued 1-year target prices for Deciphera Pharmaceuticals' stock. Their forecasts range from $10.00 to $78.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 333.7% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:

• Steven L. Hoerter, President, Chief Executive Officer & Director
• Tucker Kelly, Chief Financial Officer, Treasurer & Executive VP
• Daniel L. Flynn, Chief Scientific Officer & Executive VP
• Stephen B. Ruddy, Chief Technical Officer
• Matthew L. Sherman, Chief Medical Officer & Executive Vice President

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Deciphera Pharmaceuticals' key competitors?

Some companies that are related to Deciphera Pharmaceuticals include Global Blood Therapeutics (GBT), Erasca (ERAS), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Atai Life Sciences (ATAI), Myovant Sciences (MYOV), Nuvation Bio (NUVB), Travere Therapeutics (TVTX), IVERIC bio (ISEE), Kadmon (KDMN), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Bicycle Therapeutics (BCYC) and Verve Therapeutics (VERV).
View all of DCPH's competitors.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.32%), Franklin Resources Inc. (5.46%), ArrowMark Colorado Holdings LLC (3.10%), Suvretta Capital Management LLC (1.47%), Deerfield Management Company L.P. Series C (1.39%) and Geode Capital Management LLC (1.26%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals.

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Point72 Asset Management L.P., Artal Group S.A., International Biotechnology Trust PLC, Citigroup Inc., Russell Investments Group Ltd., Man Group plc, and Hood River Capital Management LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include James Arthur Bristol, Matthew L Sherman, and Michael Douglas Taylor.
View insider buying and selling activity for Deciphera Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Suvretta Capital Management LLC, Polar Capital Holdings Plc, Sectoral Asset Management Inc, Franklin Resources Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP, and Invesco Ltd..
View insider buying and selling activity for Deciphera Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $8.07.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals has a market capitalization of $471.94 million and generates $42.09 million in revenue each year. The company earns $-266.49 million in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 350 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Where are Deciphera Pharmaceuticals' headquarters?

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected].